These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24908424)

  • 1. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.
    El-Chaar NN; Piccolo SR; Boucher KM; Cohen AL; Chang JT; Moos PJ; Bild AH
    Mol Oncol; 2014 Oct; 8(7):1339-54. PubMed ID: 24908424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
    Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
    Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH; Kim JY; Jung JI; Han JY
    Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
    Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP
    Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.
    Guin S; Theodorescu D
    Acta Pharmacol Sin; 2015 Mar; 36(3):291-7. PubMed ID: 25557115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
    Thiagarajan PS; Wu X; Zhang W; Shi I; Bagai R; Leahy P; Feng Y; Veigl M; Lindner D; Danielpour D; Yin L; Rosell R; Bivona TG; Zhang Z; Ma PC
    Oncotarget; 2016 Dec; 7(50):82013-82027. PubMed ID: 27852038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
    Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
    Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
    Kaneto N; Yokoyama S; Hayakawa Y; Kato S; Sakurai H; Saiki I
    Cancer Sci; 2014 Jul; 105(7):788-94. PubMed ID: 24750242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
    Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP
    Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.